Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 10/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18878391 | 0.78 | GRM4 (0.45) | CFTRADORA1DYRK1BGRM4MTOR | |
| SCHEMBL14947692 | 0.76 | GRM4 (0.43) | CFTRADORA1DYRK1BGRM4MTOR | |
| SCHEMBL14947693 | 0.76 | GRM4 (0.43) | CFTRADORA1DYRK1BGRM4MTOR | |
| SCHEMBL20282465 | 0.73 | CFTR (0.44) | CFTRADORA1DYRK1BGRM4MTOR | |
| SCHEMBL14947683 | 0.72 | PLK1 (0.44) | CFTRDYRK1BGRM4 | |
| SCHEMBL20263177 | 0.72 | CFTR (0.57) | CFTR | |
| SCHEMBL20263253 | 0.71 | CFTR (0.53) | CFTR | |
| SCHEMBL3626706 | 0.70 | MAPT (0.50) | ADORA1DYRK1BGRM4MTORADORA3 | |
| SCHEMBL28170602 | 0.70 | KMT2A (0.44) | ADORA1 | |
| SCHEMBL20163069 | 0.69 | CFTR (0.43) | CFTRDYRK1BGRM4MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | TBL2, TBL3, TBL1XR1 | CFTR 1401/4885ADORA1 4264/4885DYRK1B 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.